nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—prostate cancer	0.267	1	CbGaD
Conivaptan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0827	0.207	CbGbCtD
Conivaptan—CYP3A4—Bicalutamide—prostate cancer	0.0434	0.109	CbGbCtD
Conivaptan—CYP3A4—Estramustine—prostate cancer	0.0404	0.101	CbGbCtD
Conivaptan—CYP3A4—Abiraterone—prostate cancer	0.036	0.09	CbGbCtD
Conivaptan—CYP3A4—Flutamide—prostate cancer	0.036	0.09	CbGbCtD
Conivaptan—CYP3A4—Cabazitaxel—prostate cancer	0.0266	0.0666	CbGbCtD
Conivaptan—CYP3A4—Estrone—prostate cancer	0.026	0.0651	CbGbCtD
Conivaptan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0232	0.058	CbGbCtD
Conivaptan—AVPR2—urine—prostate cancer	0.0218	0.697	CbGeAlD
Conivaptan—CYP3A4—Conjugated Estrogens—prostate cancer	0.017	0.0426	CbGbCtD
Conivaptan—CYP3A4—Mitoxantrone—prostate cancer	0.0155	0.0387	CbGbCtD
Conivaptan—CYP3A4—Estradiol—prostate cancer	0.0149	0.0374	CbGbCtD
Conivaptan—CYP3A4—Prednisone—prostate cancer	0.0128	0.0321	CbGbCtD
Conivaptan—CYP3A4—Etoposide—prostate cancer	0.00975	0.0244	CbGbCtD
Conivaptan—CYP3A4—Docetaxel—prostate cancer	0.00893	0.0223	CbGbCtD
Conivaptan—CYP3A4—Doxorubicin—prostate cancer	0.00665	0.0166	CbGbCtD
Conivaptan—AVPR2—renal system—prostate cancer	0.00533	0.171	CbGeAlD
Conivaptan—CYP3A4—urine—prostate cancer	0.00332	0.106	CbGeAlD
Conivaptan—Atorvastatin—AHR—prostate cancer	0.00138	0.294	CrCbGaD
Conivaptan—CYP3A4—renal system—prostate cancer	0.000812	0.026	CbGeAlD
Conivaptan—Deferasirox—CYP3A4—prostate cancer	0.000797	0.169	CrCbGaD
Conivaptan—Atorvastatin—CYP3A5—prostate cancer	0.000633	0.134	CrCbGaD
Conivaptan—Lomitapide—CYP3A4—prostate cancer	0.00063	0.134	CrCbGaD
Conivaptan—Tolvaptan—CYP3A4—prostate cancer	0.000561	0.119	CrCbGaD
Conivaptan—Atorvastatin—CYP2C19—prostate cancer	0.000431	0.0915	CrCbGaD
Conivaptan—Atorvastatin—CYP3A4—prostate cancer	0.000274	0.0582	CrCbGaD
Conivaptan—Nausea—Bicalutamide—prostate cancer	0.000219	0.00111	CcSEcCtD
Conivaptan—Candida infection—Doxorubicin—prostate cancer	0.000218	0.00111	CcSEcCtD
Conivaptan—Urethral disorder—Etoposide—prostate cancer	0.000217	0.0011	CcSEcCtD
Conivaptan—Pain—Conjugated Estrogens—prostate cancer	0.000217	0.0011	CcSEcCtD
Conivaptan—Constipation—Conjugated Estrogens—prostate cancer	0.000217	0.0011	CcSEcCtD
Conivaptan—Hypertension—Estradiol—prostate cancer	0.000215	0.00109	CcSEcCtD
Conivaptan—Sepsis—Epirubicin—prostate cancer	0.000214	0.00109	CcSEcCtD
Conivaptan—Anaemia—Mitoxantrone—prostate cancer	0.000214	0.00109	CcSEcCtD
Conivaptan—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000213	0.00108	CcSEcCtD
Conivaptan—Feeling abnormal—Goserelin—prostate cancer	0.000211	0.00107	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.00021	0.00107	CcSEcCtD
Conivaptan—Hypokalaemia—Prednisone—prostate cancer	0.000209	0.00106	CcSEcCtD
Conivaptan—Phlebitis—Epirubicin—prostate cancer	0.000208	0.00106	CcSEcCtD
Conivaptan—Dry mouth—Estradiol—prostate cancer	0.000207	0.00105	CcSEcCtD
Conivaptan—Pneumonia—Docetaxel—prostate cancer	0.000206	0.00105	CcSEcCtD
Conivaptan—Cardiac disorder—Etoposide—prostate cancer	0.000205	0.00105	CcSEcCtD
Conivaptan—Infestation—Docetaxel—prostate cancer	0.000205	0.00104	CcSEcCtD
Conivaptan—Infestation NOS—Docetaxel—prostate cancer	0.000205	0.00104	CcSEcCtD
Conivaptan—Confusional state—Estradiol—prostate cancer	0.000205	0.00104	CcSEcCtD
Conivaptan—Body temperature increased—Goserelin—prostate cancer	0.000202	0.00103	CcSEcCtD
Conivaptan—Infection—Estradiol—prostate cancer	0.000202	0.00103	CcSEcCtD
Conivaptan—Angiopathy—Etoposide—prostate cancer	0.000201	0.00102	CcSEcCtD
Conivaptan—Hyperglycaemia—Capecitabine—prostate cancer	0.000201	0.00102	CcSEcCtD
Conivaptan—Body temperature increased—Conjugated Estrogens—prostate cancer	0.0002	0.00102	CcSEcCtD
Conivaptan—Hypertension—Mitoxantrone—prostate cancer	0.0002	0.00102	CcSEcCtD
Conivaptan—Pneumonia—Capecitabine—prostate cancer	0.0002	0.00102	CcSEcCtD
Conivaptan—Mediastinal disorder—Etoposide—prostate cancer	0.000199	0.00101	CcSEcCtD
Conivaptan—Nervous system disorder—Estradiol—prostate cancer	0.000199	0.00101	CcSEcCtD
Conivaptan—Infestation NOS—Capecitabine—prostate cancer	0.000198	0.00101	CcSEcCtD
Conivaptan—Infestation—Capecitabine—prostate cancer	0.000198	0.00101	CcSEcCtD
Conivaptan—Sepsis—Doxorubicin—prostate cancer	0.000198	0.00101	CcSEcCtD
Conivaptan—Vomiting—Ethinyl Estradiol—prostate cancer	0.000198	0.00101	CcSEcCtD
Conivaptan—Skin disorder—Estradiol—prostate cancer	0.000197	0.001	CcSEcCtD
Conivaptan—Headache—Ethinyl Estradiol—prostate cancer	0.000195	0.000991	CcSEcCtD
Conivaptan—Urinary tract infection—Capecitabine—prostate cancer	0.000193	0.000981	CcSEcCtD
Conivaptan—Phlebitis—Doxorubicin—prostate cancer	0.000193	0.00098	CcSEcCtD
Conivaptan—Confusional state—Mitoxantrone—prostate cancer	0.000191	0.00097	CcSEcCtD
Conivaptan—Haematuria—Capecitabine—prostate cancer	0.000189	0.000962	CcSEcCtD
Conivaptan—Infection—Mitoxantrone—prostate cancer	0.000188	0.000955	CcSEcCtD
Conivaptan—Nausea—Ethinyl Estradiol—prostate cancer	0.000185	0.00094	CcSEcCtD
Conivaptan—Hypoglycaemia—Epirubicin—prostate cancer	0.000184	0.000935	CcSEcCtD
Conivaptan—Cardiac failure—Epirubicin—prostate cancer	0.000184	0.000935	CcSEcCtD
Conivaptan—Skin disorder—Mitoxantrone—prostate cancer	0.000184	0.000934	CcSEcCtD
Conivaptan—Insomnia—Estradiol—prostate cancer	0.000184	0.000934	CcSEcCtD
Conivaptan—Urinary tract disorder—Docetaxel—prostate cancer	0.000182	0.000924	CcSEcCtD
Conivaptan—Oedema peripheral—Docetaxel—prostate cancer	0.000181	0.000922	CcSEcCtD
Conivaptan—Pruritus—Goserelin—prostate cancer	0.000181	0.000921	CcSEcCtD
Conivaptan—Urethral disorder—Docetaxel—prostate cancer	0.00018	0.000917	CcSEcCtD
Conivaptan—Hyponatraemia—Epirubicin—prostate cancer	0.00018	0.000916	CcSEcCtD
Conivaptan—Pruritus—Conjugated Estrogens—prostate cancer	0.000179	0.000912	CcSEcCtD
Conivaptan—Hyperglycaemia—Prednisone—prostate cancer	0.000179	0.00091	CcSEcCtD
Conivaptan—Anaemia—Etoposide—prostate cancer	0.000178	0.000906	CcSEcCtD
Conivaptan—Hypotension—Mitoxantrone—prostate cancer	0.000177	0.000899	CcSEcCtD
Conivaptan—Urinary tract disorder—Capecitabine—prostate cancer	0.000176	0.000895	CcSEcCtD
Conivaptan—Oedema peripheral—Capecitabine—prostate cancer	0.000175	0.000893	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Estradiol—prostate cancer	0.000175	0.000891	CcSEcCtD
Conivaptan—Diarrhoea—Goserelin—prostate cancer	0.000175	0.000891	CcSEcCtD
Conivaptan—Urethral disorder—Capecitabine—prostate cancer	0.000175	0.000888	CcSEcCtD
Conivaptan—Pain—Estradiol—prostate cancer	0.000174	0.000883	CcSEcCtD
Conivaptan—Constipation—Estradiol—prostate cancer	0.000174	0.000883	CcSEcCtD
Conivaptan—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000173	0.000882	CcSEcCtD
Conivaptan—Cardiac disorder—Docetaxel—prostate cancer	0.000171	0.000868	CcSEcCtD
Conivaptan—Hypoglycaemia—Doxorubicin—prostate cancer	0.00017	0.000865	CcSEcCtD
Conivaptan—Cardiac failure—Doxorubicin—prostate cancer	0.00017	0.000865	CcSEcCtD
Conivaptan—Feeling abnormal—Estradiol—prostate cancer	0.000167	0.000851	CcSEcCtD
Conivaptan—Angiopathy—Docetaxel—prostate cancer	0.000167	0.000849	CcSEcCtD
Conivaptan—Dehydration—Epirubicin—prostate cancer	0.000167	0.000848	CcSEcCtD
Conivaptan—Hyponatraemia—Doxorubicin—prostate cancer	0.000167	0.000848	CcSEcCtD
Conivaptan—Hypertension—Etoposide—prostate cancer	0.000166	0.000846	CcSEcCtD
Conivaptan—Mediastinal disorder—Docetaxel—prostate cancer	0.000166	0.000843	CcSEcCtD
Conivaptan—Cardiac disorder—Capecitabine—prostate cancer	0.000165	0.000841	CcSEcCtD
Conivaptan—Orthostatic hypotension—Epirubicin—prostate cancer	0.000164	0.000833	CcSEcCtD
Conivaptan—Hypokalaemia—Epirubicin—prostate cancer	0.000163	0.00083	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000163	0.000829	CcSEcCtD
Conivaptan—Vomiting—Goserelin—prostate cancer	0.000163	0.000828	CcSEcCtD
Conivaptan—Constipation—Mitoxantrone—prostate cancer	0.000162	0.000822	CcSEcCtD
Conivaptan—Pain—Mitoxantrone—prostate cancer	0.000162	0.000822	CcSEcCtD
Conivaptan—Angiopathy—Capecitabine—prostate cancer	0.000162	0.000822	CcSEcCtD
Conivaptan—Vomiting—Conjugated Estrogens—prostate cancer	0.000161	0.00082	CcSEcCtD
Conivaptan—Mental disorder—Docetaxel—prostate cancer	0.000161	0.00082	CcSEcCtD
Conivaptan—Mediastinal disorder—Capecitabine—prostate cancer	0.000161	0.000817	CcSEcCtD
Conivaptan—Body temperature increased—Estradiol—prostate cancer	0.00016	0.000816	CcSEcCtD
Conivaptan—Headache—Goserelin—prostate cancer	0.00016	0.000816	CcSEcCtD
Conivaptan—Erythema—Docetaxel—prostate cancer	0.00016	0.000815	CcSEcCtD
Conivaptan—Malnutrition—Docetaxel—prostate cancer	0.00016	0.000815	CcSEcCtD
Conivaptan—Headache—Conjugated Estrogens—prostate cancer	0.000159	0.000808	CcSEcCtD
Conivaptan—Confusional state—Etoposide—prostate cancer	0.000159	0.000807	CcSEcCtD
Conivaptan—Infection—Etoposide—prostate cancer	0.000156	0.000795	CcSEcCtD
Conivaptan—Mental disorder—Capecitabine—prostate cancer	0.000156	0.000794	CcSEcCtD
Conivaptan—Feeling abnormal—Mitoxantrone—prostate cancer	0.000156	0.000793	CcSEcCtD
Conivaptan—Erythema—Capecitabine—prostate cancer	0.000155	0.000789	CcSEcCtD
Conivaptan—Malnutrition—Capecitabine—prostate cancer	0.000155	0.000789	CcSEcCtD
Conivaptan—Dehydration—Doxorubicin—prostate cancer	0.000154	0.000785	CcSEcCtD
Conivaptan—Skin disorder—Etoposide—prostate cancer	0.000153	0.000777	CcSEcCtD
Conivaptan—Nausea—Goserelin—prostate cancer	0.000152	0.000773	CcSEcCtD
Conivaptan—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000152	0.000771	CcSEcCtD
Conivaptan—Hypokalaemia—Doxorubicin—prostate cancer	0.000151	0.000768	CcSEcCtD
Conivaptan—Nausea—Conjugated Estrogens—prostate cancer	0.000151	0.000766	CcSEcCtD
Conivaptan—Body temperature increased—Mitoxantrone—prostate cancer	0.000149	0.00076	CcSEcCtD
Conivaptan—Anaemia—Docetaxel—prostate cancer	0.000148	0.000753	CcSEcCtD
Conivaptan—Hypotension—Etoposide—prostate cancer	0.000147	0.000748	CcSEcCtD
Conivaptan—Angiopathy—Prednisone—prostate cancer	0.000144	0.000732	CcSEcCtD
Conivaptan—Pruritus—Estradiol—prostate cancer	0.000144	0.00073	CcSEcCtD
Conivaptan—Anaemia—Capecitabine—prostate cancer	0.000143	0.000729	CcSEcCtD
Conivaptan—Pollakiuria—Epirubicin—prostate cancer	0.000143	0.000728	CcSEcCtD
Conivaptan—Hyperglycaemia—Epirubicin—prostate cancer	0.00014	0.000711	CcSEcCtD
Conivaptan—Pneumonia—Epirubicin—prostate cancer	0.000139	0.000707	CcSEcCtD
Conivaptan—Mental disorder—Prednisone—prostate cancer	0.000139	0.000707	CcSEcCtD
Conivaptan—Diarrhoea—Estradiol—prostate cancer	0.000139	0.000706	CcSEcCtD
Conivaptan—Hypertension—Docetaxel—prostate cancer	0.000138	0.000703	CcSEcCtD
Conivaptan—Infestation NOS—Epirubicin—prostate cancer	0.000138	0.000703	CcSEcCtD
Conivaptan—Infestation—Epirubicin—prostate cancer	0.000138	0.000703	CcSEcCtD
Conivaptan—Erythema—Prednisone—prostate cancer	0.000138	0.000703	CcSEcCtD
Conivaptan—Malnutrition—Prednisone—prostate cancer	0.000138	0.000703	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Etoposide—prostate cancer	0.000136	0.000691	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000135	0.000689	CcSEcCtD
Conivaptan—Constipation—Etoposide—prostate cancer	0.000134	0.000684	CcSEcCtD
Conivaptan—Pain—Etoposide—prostate cancer	0.000134	0.000684	CcSEcCtD
Conivaptan—Urinary tract infection—Epirubicin—prostate cancer	0.000134	0.000683	CcSEcCtD
Conivaptan—Hypertension—Capecitabine—prostate cancer	0.000134	0.000681	CcSEcCtD
Conivaptan—Dry mouth—Docetaxel—prostate cancer	0.000133	0.000678	CcSEcCtD
Conivaptan—Pollakiuria—Doxorubicin—prostate cancer	0.000133	0.000674	CcSEcCtD
Conivaptan—Haematuria—Epirubicin—prostate cancer	0.000132	0.00067	CcSEcCtD
Conivaptan—Confusional state—Docetaxel—prostate cancer	0.000132	0.00067	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000131	0.000667	CcSEcCtD
Conivaptan—Infection—Docetaxel—prostate cancer	0.00013	0.00066	CcSEcCtD
Conivaptan—Feeling abnormal—Etoposide—prostate cancer	0.00013	0.000659	CcSEcCtD
Conivaptan—Hyperglycaemia—Doxorubicin—prostate cancer	0.000129	0.000658	CcSEcCtD
Conivaptan—Diarrhoea—Mitoxantrone—prostate cancer	0.000129	0.000658	CcSEcCtD
Conivaptan—Dry mouth—Capecitabine—prostate cancer	0.000129	0.000657	CcSEcCtD
Conivaptan—Vomiting—Estradiol—prostate cancer	0.000129	0.000656	CcSEcCtD
Conivaptan—Pneumonia—Doxorubicin—prostate cancer	0.000129	0.000654	CcSEcCtD
Conivaptan—Nervous system disorder—Docetaxel—prostate cancer	0.000128	0.000652	CcSEcCtD
Conivaptan—Infestation NOS—Doxorubicin—prostate cancer	0.000128	0.000651	CcSEcCtD
Conivaptan—Infestation—Doxorubicin—prostate cancer	0.000128	0.000651	CcSEcCtD
Conivaptan—Anaemia—Prednisone—prostate cancer	0.000128	0.000649	CcSEcCtD
Conivaptan—Confusional state—Capecitabine—prostate cancer	0.000128	0.000649	CcSEcCtD
Conivaptan—Headache—Estradiol—prostate cancer	0.000127	0.000647	CcSEcCtD
Conivaptan—Skin disorder—Docetaxel—prostate cancer	0.000127	0.000646	CcSEcCtD
Conivaptan—Infection—Capecitabine—prostate cancer	0.000126	0.000639	CcSEcCtD
Conivaptan—Body temperature increased—Etoposide—prostate cancer	0.000124	0.000632	CcSEcCtD
Conivaptan—Urinary tract infection—Doxorubicin—prostate cancer	0.000124	0.000632	CcSEcCtD
Conivaptan—Nervous system disorder—Capecitabine—prostate cancer	0.000124	0.000631	CcSEcCtD
Conivaptan—Skin disorder—Capecitabine—prostate cancer	0.000123	0.000625	CcSEcCtD
Conivaptan—Urinary tract disorder—Epirubicin—prostate cancer	0.000123	0.000623	CcSEcCtD
Conivaptan—Oedema peripheral—Epirubicin—prostate cancer	0.000122	0.000622	CcSEcCtD
Conivaptan—Hypotension—Docetaxel—prostate cancer	0.000122	0.000621	CcSEcCtD
Conivaptan—Haematuria—Doxorubicin—prostate cancer	0.000122	0.00062	CcSEcCtD
Conivaptan—Urethral disorder—Epirubicin—prostate cancer	0.000122	0.000619	CcSEcCtD
Conivaptan—Nausea—Estradiol—prostate cancer	0.000121	0.000613	CcSEcCtD
Conivaptan—Vomiting—Mitoxantrone—prostate cancer	0.00012	0.000612	CcSEcCtD
Conivaptan—Hypertension—Prednisone—prostate cancer	0.000119	0.000607	CcSEcCtD
Conivaptan—Headache—Mitoxantrone—prostate cancer	0.000118	0.000603	CcSEcCtD
Conivaptan—Hypotension—Capecitabine—prostate cancer	0.000118	0.000601	CcSEcCtD
Conivaptan—Insomnia—Docetaxel—prostate cancer	0.000118	0.000601	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000117	0.000594	CcSEcCtD
Conivaptan—Cardiac disorder—Epirubicin—prostate cancer	0.000115	0.000586	CcSEcCtD
Conivaptan—Insomnia—Capecitabine—prostate cancer	0.000114	0.000582	CcSEcCtD
Conivaptan—Urinary tract disorder—Doxorubicin—prostate cancer	0.000113	0.000577	CcSEcCtD
Conivaptan—Oedema peripheral—Doxorubicin—prostate cancer	0.000113	0.000575	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000113	0.000574	CcSEcCtD
Conivaptan—Angiopathy—Epirubicin—prostate cancer	0.000113	0.000573	CcSEcCtD
Conivaptan—Urethral disorder—Doxorubicin—prostate cancer	0.000113	0.000572	CcSEcCtD
Conivaptan—Nausea—Mitoxantrone—prostate cancer	0.000112	0.000571	CcSEcCtD
Conivaptan—Infection—Prednisone—prostate cancer	0.000112	0.00057	CcSEcCtD
Conivaptan—Mediastinal disorder—Epirubicin—prostate cancer	0.000112	0.000569	CcSEcCtD
Conivaptan—Constipation—Docetaxel—prostate cancer	0.000112	0.000569	CcSEcCtD
Conivaptan—Pain—Docetaxel—prostate cancer	0.000112	0.000569	CcSEcCtD
Conivaptan—Pruritus—Etoposide—prostate cancer	0.000111	0.000566	CcSEcCtD
Conivaptan—Nervous system disorder—Prednisone—prostate cancer	0.000111	0.000562	CcSEcCtD
Conivaptan—Skin disorder—Prednisone—prostate cancer	0.000109	0.000557	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000109	0.000556	CcSEcCtD
Conivaptan—Mental disorder—Epirubicin—prostate cancer	0.000109	0.000553	CcSEcCtD
Conivaptan—Constipation—Capecitabine—prostate cancer	0.000108	0.00055	CcSEcCtD
Conivaptan—Pain—Capecitabine—prostate cancer	0.000108	0.00055	CcSEcCtD
Conivaptan—Malnutrition—Epirubicin—prostate cancer	0.000108	0.000549	CcSEcCtD
Conivaptan—Erythema—Epirubicin—prostate cancer	0.000108	0.000549	CcSEcCtD
Conivaptan—Feeling abnormal—Docetaxel—prostate cancer	0.000108	0.000548	CcSEcCtD
Conivaptan—Diarrhoea—Etoposide—prostate cancer	0.000108	0.000547	CcSEcCtD
Conivaptan—Cardiac disorder—Doxorubicin—prostate cancer	0.000107	0.000542	CcSEcCtD
Conivaptan—Feeling abnormal—Capecitabine—prostate cancer	0.000104	0.00053	CcSEcCtD
Conivaptan—Angiopathy—Doxorubicin—prostate cancer	0.000104	0.00053	CcSEcCtD
Conivaptan—Mediastinal disorder—Doxorubicin—prostate cancer	0.000103	0.000526	CcSEcCtD
Conivaptan—Body temperature increased—Docetaxel—prostate cancer	0.000103	0.000526	CcSEcCtD
Conivaptan—Insomnia—Prednisone—prostate cancer	0.000102	0.000519	CcSEcCtD
Conivaptan—Mental disorder—Doxorubicin—prostate cancer	0.000101	0.000512	CcSEcCtD
Conivaptan—Body temperature increased—Capecitabine—prostate cancer	0.0001	0.000509	CcSEcCtD
Conivaptan—Vomiting—Etoposide—prostate cancer	0.0001	0.000509	CcSEcCtD
Conivaptan—Malnutrition—Doxorubicin—prostate cancer	9.99e-05	0.000508	CcSEcCtD
Conivaptan—Erythema—Doxorubicin—prostate cancer	9.99e-05	0.000508	CcSEcCtD
Conivaptan—Anaemia—Epirubicin—prostate cancer	9.98e-05	0.000508	CcSEcCtD
Conivaptan—Headache—Etoposide—prostate cancer	9.85e-05	0.000501	CcSEcCtD
Conivaptan—Constipation—Prednisone—prostate cancer	9.64e-05	0.00049	CcSEcCtD
Conivaptan—Nausea—Etoposide—prostate cancer	9.34e-05	0.000475	CcSEcCtD
Conivaptan—Hypertension—Epirubicin—prostate cancer	9.33e-05	0.000474	CcSEcCtD
Conivaptan—Feeling abnormal—Prednisone—prostate cancer	9.29e-05	0.000472	CcSEcCtD
Conivaptan—Pruritus—Docetaxel—prostate cancer	9.25e-05	0.00047	CcSEcCtD
Conivaptan—Anaemia—Doxorubicin—prostate cancer	9.24e-05	0.00047	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	9.13e-05	0.000465	CcSEcCtD
Conivaptan—Dry mouth—Epirubicin—prostate cancer	8.99e-05	0.000457	CcSEcCtD
Conivaptan—Pruritus—Capecitabine—prostate cancer	8.95e-05	0.000455	CcSEcCtD
Conivaptan—Diarrhoea—Docetaxel—prostate cancer	8.94e-05	0.000455	CcSEcCtD
Conivaptan—Body temperature increased—Prednisone—prostate cancer	8.91e-05	0.000453	CcSEcCtD
Conivaptan—Confusional state—Epirubicin—prostate cancer	8.89e-05	0.000452	CcSEcCtD
Conivaptan—Infection—Epirubicin—prostate cancer	8.76e-05	0.000446	CcSEcCtD
Conivaptan—Diarrhoea—Capecitabine—prostate cancer	8.66e-05	0.00044	CcSEcCtD
Conivaptan—Nervous system disorder—Epirubicin—prostate cancer	8.65e-05	0.00044	CcSEcCtD
Conivaptan—Hypertension—Doxorubicin—prostate cancer	8.63e-05	0.000439	CcSEcCtD
Conivaptan—Skin disorder—Epirubicin—prostate cancer	8.56e-05	0.000436	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.45e-05	0.00043	CcSEcCtD
Conivaptan—Dry mouth—Doxorubicin—prostate cancer	8.32e-05	0.000423	CcSEcCtD
Conivaptan—Vomiting—Docetaxel—prostate cancer	8.31e-05	0.000423	CcSEcCtD
Conivaptan—Hypotension—Epirubicin—prostate cancer	8.24e-05	0.000419	CcSEcCtD
Conivaptan—Confusional state—Doxorubicin—prostate cancer	8.22e-05	0.000418	CcSEcCtD
Conivaptan—Headache—Docetaxel—prostate cancer	8.19e-05	0.000416	CcSEcCtD
Conivaptan—Infection—Doxorubicin—prostate cancer	8.1e-05	0.000412	CcSEcCtD
Conivaptan—Vomiting—Capecitabine—prostate cancer	8.05e-05	0.000409	CcSEcCtD
Conivaptan—Nervous system disorder—Doxorubicin—prostate cancer	8e-05	0.000407	CcSEcCtD
Conivaptan—Pruritus—Prednisone—prostate cancer	7.97e-05	0.000406	CcSEcCtD
Conivaptan—Insomnia—Epirubicin—prostate cancer	7.97e-05	0.000406	CcSEcCtD
Conivaptan—Headache—Capecitabine—prostate cancer	7.93e-05	0.000403	CcSEcCtD
Conivaptan—Skin disorder—Doxorubicin—prostate cancer	7.92e-05	0.000403	CcSEcCtD
Conivaptan—Nausea—Docetaxel—prostate cancer	7.76e-05	0.000395	CcSEcCtD
Conivaptan—Diarrhoea—Prednisone—prostate cancer	7.71e-05	0.000392	CcSEcCtD
Conivaptan—Hypotension—Doxorubicin—prostate cancer	7.62e-05	0.000388	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Epirubicin—prostate cancer	7.61e-05	0.000387	CcSEcCtD
Conivaptan—Constipation—Epirubicin—prostate cancer	7.54e-05	0.000383	CcSEcCtD
Conivaptan—Pain—Epirubicin—prostate cancer	7.54e-05	0.000383	CcSEcCtD
Conivaptan—Nausea—Capecitabine—prostate cancer	7.52e-05	0.000382	CcSEcCtD
Conivaptan—Insomnia—Doxorubicin—prostate cancer	7.38e-05	0.000375	CcSEcCtD
Conivaptan—Feeling abnormal—Epirubicin—prostate cancer	7.26e-05	0.00037	CcSEcCtD
Conivaptan—Vomiting—Prednisone—prostate cancer	7.17e-05	0.000365	CcSEcCtD
Conivaptan—Headache—Prednisone—prostate cancer	7.06e-05	0.000359	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Doxorubicin—prostate cancer	7.04e-05	0.000358	CcSEcCtD
Conivaptan—Pain—Doxorubicin—prostate cancer	6.98e-05	0.000355	CcSEcCtD
Conivaptan—Constipation—Doxorubicin—prostate cancer	6.98e-05	0.000355	CcSEcCtD
Conivaptan—Body temperature increased—Epirubicin—prostate cancer	6.97e-05	0.000354	CcSEcCtD
Conivaptan—Feeling abnormal—Doxorubicin—prostate cancer	6.72e-05	0.000342	CcSEcCtD
Conivaptan—Nausea—Prednisone—prostate cancer	6.7e-05	0.000341	CcSEcCtD
Conivaptan—Body temperature increased—Doxorubicin—prostate cancer	6.45e-05	0.000328	CcSEcCtD
Conivaptan—Pruritus—Epirubicin—prostate cancer	6.24e-05	0.000317	CcSEcCtD
Conivaptan—Diarrhoea—Epirubicin—prostate cancer	6.03e-05	0.000307	CcSEcCtD
Conivaptan—Pruritus—Doxorubicin—prostate cancer	5.77e-05	0.000294	CcSEcCtD
Conivaptan—Vomiting—Epirubicin—prostate cancer	5.6e-05	0.000285	CcSEcCtD
Conivaptan—Diarrhoea—Doxorubicin—prostate cancer	5.58e-05	0.000284	CcSEcCtD
Conivaptan—Headache—Epirubicin—prostate cancer	5.52e-05	0.000281	CcSEcCtD
Conivaptan—Nausea—Epirubicin—prostate cancer	5.24e-05	0.000266	CcSEcCtD
Conivaptan—Vomiting—Doxorubicin—prostate cancer	5.19e-05	0.000264	CcSEcCtD
Conivaptan—Headache—Doxorubicin—prostate cancer	5.11e-05	0.00026	CcSEcCtD
Conivaptan—Nausea—Doxorubicin—prostate cancer	4.84e-05	0.000246	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—ITPR1—prostate cancer	3.47e-05	0.000344	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ITPR1—prostate cancer	3.45e-05	0.000342	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CB—prostate cancer	3.44e-05	0.000341	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.44e-05	0.000341	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CB—prostate cancer	3.41e-05	0.000339	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF1R—prostate cancer	3.32e-05	0.000329	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.3e-05	0.000328	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL8—prostate cancer	3.3e-05	0.000328	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF1R—prostate cancer	3.3e-05	0.000327	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—JAK2—prostate cancer	3.29e-05	0.000326	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL8—prostate cancer	3.28e-05	0.000326	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—JAK2—prostate cancer	3.26e-05	0.000324	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.26e-05	0.000323	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.2e-05	0.000318	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LPL—prostate cancer	3.18e-05	0.000316	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LPL—prostate cancer	3.16e-05	0.000314	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—prostate cancer	3.16e-05	0.000313	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PDGFRB—prostate cancer	3.15e-05	0.000313	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.15e-05	0.000313	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—prostate cancer	3.14e-05	0.000311	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PDGFRB—prostate cancer	3.13e-05	0.000311	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CB—prostate cancer	3.12e-05	0.00031	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	3.11e-05	0.000308	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CB—prostate cancer	3.1e-05	0.000308	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ITGB3—prostate cancer	3.07e-05	0.000305	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	3.06e-05	0.000304	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ITGB3—prostate cancer	3.05e-05	0.000303	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL8—prostate cancer	3e-05	0.000298	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—RXRA—prostate cancer	3e-05	0.000298	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ERBB3—prostate cancer	2.98e-05	0.000296	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCL8—prostate cancer	2.98e-05	0.000296	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGFR2—prostate cancer	2.98e-05	0.000295	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ERBB3—prostate cancer	2.96e-05	0.000294	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGFR2—prostate cancer	2.96e-05	0.000293	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—COMT—prostate cancer	2.89e-05	0.000287	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.87e-05	0.000285	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—prostate cancer	2.87e-05	0.000285	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TERT—prostate cancer	2.86e-05	0.000284	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.85e-05	0.000283	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—prostate cancer	2.85e-05	0.000283	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TERT—prostate cancer	2.84e-05	0.000281	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.84e-05	0.000281	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HIF1A—prostate cancer	2.73e-05	0.000271	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HIF1A—prostate cancer	2.71e-05	0.000269	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LEP—prostate cancer	2.67e-05	0.000265	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LEP—prostate cancer	2.65e-05	0.000263	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CAV1—prostate cancer	2.64e-05	0.000262	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.64e-05	0.000262	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CAV1—prostate cancer	2.62e-05	0.00026	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KDR—prostate cancer	2.61e-05	0.000259	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.61e-05	0.000259	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KDR—prostate cancer	2.59e-05	0.000257	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ESR1—prostate cancer	2.55e-05	0.000253	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ESR1—prostate cancer	2.53e-05	0.000251	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.5e-05	0.000249	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BAD—prostate cancer	2.49e-05	0.000247	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HAO1—prostate cancer	2.47e-05	0.000245	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.47e-05	0.000245	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BAD—prostate cancer	2.47e-05	0.000245	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—APC—prostate cancer	2.41e-05	0.000239	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CG—prostate cancer	2.41e-05	0.000239	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—APC—prostate cancer	2.39e-05	0.000237	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CG—prostate cancer	2.39e-05	0.000237	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EGF—prostate cancer	2.38e-05	0.000236	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IRS1—prostate cancer	2.38e-05	0.000236	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EGF—prostate cancer	2.36e-05	0.000234	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IRS1—prostate cancer	2.36e-05	0.000234	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GSK3B—prostate cancer	2.31e-05	0.000229	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GSK3B—prostate cancer	2.29e-05	0.000228	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—INS—prostate cancer	2.28e-05	0.000226	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—INS—prostate cancer	2.26e-05	0.000225	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CREBBP—prostate cancer	2.23e-05	0.000221	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CREBBP—prostate cancer	2.22e-05	0.00022	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF1—prostate cancer	2.2e-05	0.000219	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—EGFR—prostate cancer	2.19e-05	0.000218	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF1—prostate cancer	2.19e-05	0.000217	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—EGFR—prostate cancer	2.18e-05	0.000216	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAP2K1—prostate cancer	2.13e-05	0.000211	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CD—prostate cancer	2.12e-05	0.00021	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAP2K1—prostate cancer	2.12e-05	0.00021	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CD—prostate cancer	2.1e-05	0.000208	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CA—prostate cancer	2.1e-05	0.000208	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SERPINE1—prostate cancer	2.09e-05	0.000208	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CA—prostate cancer	2.08e-05	0.000207	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SERPINE1—prostate cancer	2.08e-05	0.000206	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KRAS—prostate cancer	2.07e-05	0.000206	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KRAS—prostate cancer	2.06e-05	0.000204	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGF2—prostate cancer	2.03e-05	0.000201	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CSAD—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADI1—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CBR1—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GRHL1—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TST—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSAT1—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGF2—prostate cancer	2.01e-05	0.0002	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NOS3—prostate cancer	2e-05	0.000198	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NOS3—prostate cancer	1.98e-05	0.000197	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—JAK2—prostate cancer	1.94e-05	0.000193	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—JAK2—prostate cancer	1.93e-05	0.000191	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CA—prostate cancer	1.9e-05	0.000189	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MDM2—prostate cancer	1.9e-05	0.000188	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CA—prostate cancer	1.89e-05	0.000188	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MDM2—prostate cancer	1.88e-05	0.000187	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.87e-05	0.000186	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CKMT2—prostate cancer	1.87e-05	0.000186	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GRHPR—prostate cancer	1.87e-05	0.000186	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.87e-05	0.000186	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ERBB2—prostate cancer	1.87e-05	0.000185	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ERBB2—prostate cancer	1.86e-05	0.000184	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CB—prostate cancer	1.84e-05	0.000183	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CB—prostate cancer	1.83e-05	0.000182	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCL8—prostate cancer	1.77e-05	0.000176	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM3—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AOX1—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RFK—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PGAM2—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NAGLU—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL8—prostate cancer	1.76e-05	0.000175	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1B—prostate cancer	1.73e-05	0.000172	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1B—prostate cancer	1.72e-05	0.000171	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKT1—prostate cancer	1.71e-05	0.00017	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AKT1—prostate cancer	1.7e-05	0.000169	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CASP3—prostate cancer	1.7e-05	0.000168	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—prostate cancer	1.69e-05	0.000168	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—prostate cancer	1.69e-05	0.000167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CASP3—prostate cancer	1.68e-05	0.000167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—prostate cancer	1.68e-05	0.000167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AMACR—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NAT1—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—DEGS1—prostate cancer	1.67e-05	0.000166	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—prostate cancer	1.65e-05	0.000164	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—prostate cancer	1.64e-05	0.000163	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CTNNB1—prostate cancer	1.64e-05	0.000162	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CTNNB1—prostate cancer	1.62e-05	0.000161	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MMP9—prostate cancer	1.6e-05	0.000159	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1A—prostate cancer	1.6e-05	0.000159	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTEN—prostate cancer	1.59e-05	0.000158	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.59e-05	0.000158	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MMP9—prostate cancer	1.59e-05	0.000158	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1A—prostate cancer	1.59e-05	0.000157	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTEN—prostate cancer	1.58e-05	0.000157	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKT1—prostate cancer	1.56e-05	0.000154	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKT1—prostate cancer	1.54e-05	0.000153	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EP300—prostate cancer	1.52e-05	0.000151	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EP300—prostate cancer	1.51e-05	0.00015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SRC—prostate cancer	1.48e-05	0.000147	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SRC—prostate cancer	1.47e-05	0.000146	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VEGFA—prostate cancer	1.44e-05	0.000143	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VEGFA—prostate cancer	1.43e-05	0.000142	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STAT3—prostate cancer	1.43e-05	0.000141	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HPGD—prostate cancer	1.42e-05	0.000141	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.42e-05	0.000141	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STAT3—prostate cancer	1.42e-05	0.00014	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.33e-05	0.000132	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—prostate cancer	1.32e-05	0.000131	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—prostate cancer	1.32e-05	0.000131	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—prostate cancer	1.32e-05	0.000131	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—prostate cancer	1.31e-05	0.00013	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MTAP—prostate cancer	1.3e-05	0.000129	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.3e-05	0.000129	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EGFR—prostate cancer	1.3e-05	0.000129	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EGFR—prostate cancer	1.29e-05	0.000128	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.27e-05	0.000126	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.27e-05	0.000126	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KRAS—prostate cancer	1.22e-05	0.000121	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KRAS—prostate cancer	1.22e-05	0.000121	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.21e-05	0.00012	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ACSL4—prostate cancer	1.21e-05	0.00012	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PHGDH—prostate cancer	1.16e-05	0.000115	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UMPS—prostate cancer	1.16e-05	0.000115	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ARG2—prostate cancer	1.16e-05	0.000115	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LDHB—prostate cancer	1.13e-05	0.000113	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CA—prostate cancer	1.12e-05	0.000112	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CA—prostate cancer	1.12e-05	0.000111	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.11e-05	0.000111	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—prostate cancer	1.09e-05	0.000108	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PDHA1—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TCN2—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UCP3—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA3—prostate cancer	1.08e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.03e-05	0.000102	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.03e-05	0.000102	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—prostate cancer	9.96e-06	9.88e-05	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—prostate cancer	9.89e-06	9.81e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA4—prostate cancer	9.84e-06	9.76e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.84e-06	9.76e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA2—prostate cancer	9.59e-06	9.51e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SULT1A1—prostate cancer	9.47e-06	9.4e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ABCG5—prostate cancer	9.47e-06	9.4e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA1—prostate cancer	9.25e-06	9.18e-05	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKT1—prostate cancer	9.19e-06	9.12e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTO1—prostate cancer	9.15e-06	9.08e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HSD3B2—prostate cancer	9.15e-06	9.08e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NAT2—prostate cancer	9.15e-06	9.08e-05	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKT1—prostate cancer	9.12e-06	9.05e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PLCB2—prostate cancer	8.77e-06	8.7e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LRP2—prostate cancer	8.77e-06	8.7e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.77e-06	8.7e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—P4HB—prostate cancer	8.6e-06	8.53e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC22A1—prostate cancer	8.37e-06	8.3e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SULT2A1—prostate cancer	8.15e-06	8.09e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MED12—prostate cancer	8.02e-06	7.96e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GNG5—prostate cancer	7.96e-06	7.9e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NCOA3—prostate cancer	7.67e-06	7.61e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HPGDS—prostate cancer	7.31e-06	7.26e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2C19—prostate cancer	7.27e-06	7.21e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ACHE—prostate cancer	7.09e-06	7.04e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTT1—prostate cancer	7.09e-06	7.04e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2A6—prostate cancer	7.01e-06	6.96e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.82e-06	6.77e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PRKACB—prostate cancer	6.78e-06	6.73e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.71e-06	6.66e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NCOA2—prostate cancer	6.4e-06	6.35e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC5A5—prostate cancer	6.1e-06	6.06e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.96e-06	5.92e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NQO1—prostate cancer	5.89e-06	5.85e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TH—prostate cancer	5.81e-06	5.76e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.65e-06	5.61e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GGT1—prostate cancer	5.47e-06	5.43e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NCOA1—prostate cancer	5.39e-06	5.35e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.31e-06	5.27e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RXRA—prostate cancer	5.13e-06	5.09e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—COMT—prostate cancer	4.94e-06	4.9e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTP1—prostate cancer	4.92e-06	4.88e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ITPR1—prostate cancer	4.84e-06	4.8e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TYMS—prostate cancer	4.57e-06	4.54e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—prostate cancer	4.52e-06	4.48e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LPL—prostate cancer	4.43e-06	4.4e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.28e-06	4.25e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ERCC2—prostate cancer	4.25e-06	4.21e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MTHFR—prostate cancer	3.99e-06	3.96e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PPARA—prostate cancer	3.92e-06	3.89e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CAV1—prostate cancer	3.68e-06	3.65e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.35e-06	3.33e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—INS—prostate cancer	3.18e-06	3.15e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CREBBP—prostate cancer	3.11e-06	3.09e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.95e-06	2.93e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NOS3—prostate cancer	2.78e-06	2.76e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.57e-06	2.55e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—prostate cancer	2.55e-06	2.53e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTEN—prostate cancer	2.22e-06	2.2e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—EP300—prostate cancer	2.12e-06	2.1e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.57e-06	1.55e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AKT1—prostate cancer	1.28e-06	1.27e-05	CbGpPWpGaD
